Table 4 Published studies on immunotherapy response in syngeneic murine models
Reference | Model | Tumor cells Inoculated | Tumor size (mm3) | Time to start treating (d) | Outcome |
|---|---|---|---|---|---|
Kim et al. PNAS 2014 | 4T1 | 5.00E6 | 400 | 11 | Tumor eradication with PD-1/CTLA-4 at day 15 |
CT26 | 5.00E6 | 400 | 11 | Tumor eradication with PD-1/CTLA-4 at day 15 | |
Lian et al Sci Rep 2019 | 4T1 | 1.00E5 | Not reported | 24 | PD-L1/CD74 dual blockade reduced lung metastasis |
Clift et al. Cancer Res 2019 | 4T1/EMT6 | 1.00E5 | 100-150 | Not reported | PD-L1 blockade +PVHA inhibited tumor growth |
Sun et al. Mol Cancer Ther 2020 | 4T1 | 1.00E6 | 100-150 | 3 | CTLA-4 and PD-1 blockade promoted T cell infiltration |
Xie et al. J Immunother Cancer 2018 | 4T1 | 5.00E6 | <200 | 5,8 | AngII blockade enhances sensitivity to CTLA-4/PD-1 treatment. |
Xu et al. Clin Cancer Res 2017 | EMT6 | 5.00E6 | Not reported | Not reported | NHS-muIL12 and avelumab combination therapy enhanced antitumor efficacy relative to either monotherapy |
Knudson et al. Oncoimmunology 2018 | EMT6 | 2.50E5 | 50-100 | Not reported | Bifunctional checkpoint inhibitor of TGFβRII linked to the C-terminus of human anti-PD-L1 heavy chain reduced tumor burden. |
4T1 | 5.00E4 | 50-100 | Not reported | ||
Zippelius et al. Cancer Immunol Res 2015 | EMT6 | 2.50E5 | Not reported | 16 | PD-L1 overexpression mediates acquired resistance to agonistic anti-CD40 treatment. |
MC38 | 1.00E6 | Not reported | 16 | ||
Lewis et al. Oncoimmunology 2017 | EMT6 | 1.50E6 | Not reported | 7 | IL-21 inhibition with CTLA4 blockade promoted tumor regression compared to monotherapy. |
Li et al. Cancer Cell 2018 | 4T1 | 5.00E4 | <200 | 6 | A monoclonal antibody targeting glycosylated PD-L1 (gPD-L1) blocks PD-L1/PD-1 interaction and promotes PD-L1 internalization and degradation. |
EMT6 | 5.00E4 | <200 | 6 | ||
Liu et al. Cancer Discovery 2016 | 4T1.2 | 2.00E4 | 40-80 | 16 | Neo-adjuvant PD-1/CD-137 therapy had better efficacy than adjuvant |
4T1.2 | 5.00E4 | 40-80 | 10 | Increase in tumor-specific CD8+ T cells after neoadjuvant anti-PD-1+anti-CD137 therapy | |
E0771 | 5.00E4 | 40-80 | 16-18 | Neo-adjuvant PD-1+CD-137 therapy had better efficacy than adjuvant. | |
Liu et al. Oncoimmunology 2019 | E0771 | 2.00E5 | 50 | 10 | Guadecitabine was similarly effective in the E0771 model of murine breast carcinoma. Finally, we found that guadecitabine in combination with AIT resulted in prolonged survival in both 4 T1 and E0771 breast cancer models. |
4T1 | 5.00E4 | 50 | 10 | ||
Kasikara et al. Cancer Res 2019 | E0771 | 1.00E5 | Not reported | 10 | Combination of TAM inhibitor (BMS-777607) and anti-PD-1 improved tumor efficacy by altering the TME. |
Messenheimer et al. Clin Cancer Res 2017 | MMTV-PyMT | 1.00E6 | <50 | 7 | Sequential combination of anti-OX40 and anti-PD-1 increased efficacy. |
Nolan et al. Sci Transl Med 2017 | MMTV-cre/Brca1fl/fl /p53+/- | 4.00E4 | 100 | 21 | Cisplatin treatment combined with dual anti–PD-1 and anti-CTLA-4 therapy substantially augmented antitumor immunity in Brca1-deficient mice. |
Young et al. Plos One 2016 | MMTV-PyMT | 1.00E6 | Not reported | 14 | Combination treatment with anti-CTLA4, anti-OX40 and radiation resulted in significantly extended survival. |